Biotech innovator Alumis, focused on autoimmune therapies, reported a significant insider buy amid a year of robust stock ...

Single-ascending doses of MAR002 showed a favourable tolerability and safety profile with no drug-related safety signals ...

Neurosterix was spun-out of Addex in April 2024, raising $65 million in a Series A financing led by funds affiliated with ...

"GRIN Therapeutics begins Phase III trial of radiprodil for NDD" was originally created and published by Clinical Trials ...

Addex spin-out Neurosterix begins phase 1 study with M4 PAM - NTX-253 for schizophrenia: Geneva, Switzerland Thursday, January 8, 2026, 12:00 Hrs [IST] Addex Therapeutics, a clini ...

China NMPA approves Sanofi’s Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome: Paris Saturday, January 17, 2026, 11:00 Hrs ...

To request an in-person meeting with Gain management on Wednesday during the week of the J.P. Morgan Healthcare Conference, either register at LifeSci Partners Corporate Access Event 2026 or contact ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers ...

PRNewswire/ -- iOnctura, a clinical-stage biopharmaceutical company developing precision oral small molecules for neglected ...

Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.

Ad Hoc Announcement Pursuant to Art.?53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics(SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing ...